CagriSema
Filed with FDA in December 2025; decision expected by end of 2026.
Two peptides in one weekly injection: cagrilintide, a long-acting copy of the fullness hormone , and semaglutide. Filed with and awaiting a decision. Made by Novo Nordisk, also called Cagrilintide + semaglutide.
What the evidence shows
Side effects and risks
Who should avoid it: Anyone outside a clinical trial.
How it works
- Where it acts
- Amylin receptors (cagrilintide) and GLP-1 receptors (semaglutide) in the brain and gut.
- What it changes
- Two fullness signals at once, plus a slower-emptying stomach.
- What people notice
- In trials, more weight loss than semaglutide alone. Stomach side effects are common.
How it has been given in trials
Weekly injection under the skin: 2.4 mg of each component after a stepwise increase. There is no approved dose yet.
Getting it in the United States
The legal route for CagriSema
Filed with the regulator and not yet approved. Until a decision, clinical trials are the only lawful route.
Awaiting approval, trials only
Not yet on sale. Novo filed with the FDA in 2025-12 and a decision is expected by late 2026. Until then the lawful route is a Novo trial.
Source: Drug Topics, 2026-02
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
More contextWhat public figures say, videos and articles and when options run out
What experts and influencers say
Paraphrased from the linked sources.
Said the diabetes-trial result looked about the same as tirzepatide across trials and that tirzepatide may hold an edge because CagriSema is harder to manufacture.
Source: BioSpace, 2025-03
Leerink PartnersSourceWarns against
Said CagriSema results looked very similar to semaglutide and tirzepatide and were not enough to fend off future competitors.
Source: CNBC via NBC10, 2025-03
BofA Global ResearchSourceWarns against
After CagriSema fell short of forecasts in 2025, she said investor sentiment toward Novo was as negative as it had ever been, but called the share price reaction out of proportion.
Source: CNBC via NBC10, 2025-03
Emily FieldSourceMixed view
Said Novo was pleased with 23 percent weight loss in REDEFINE 4, although the trial missed its goal of matching tirzepatide. He pointed to a planned higher-dose trial.
Source: Drug Topics, 2026-02
Martin Holst LangeWebsiteRecommends
Money: Novo Nordisk executive
Photo source: jcst2d.com
Said his firm was not sure CagriSema is best in class and that investors did not yet see it as a real alternative, though he expected they eventually would.
Source: CNBC via NBC10, 2025-03
Soren LontoftSourceMixed view
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Novo Nordisk's amylin obesity drug keeps performing like Zepbound
Elaine Chen, STAT reporter
Late-stage CagriSema results looked similar to Zepbound on safety and weight loss, disappointing investors, with weight loss appearing to level off by week 68.
A sober, outcome-focused look at how CagriSema stacks up.
ADA 25: Efficacy and Safety of CagriSema in REDEFINE 1 and 2
Conference presentation of the REDEFINE 1 and 2 phase 3 trials, covering CagriSema's weight loss and safety in people with obesity.
Primary trial data presented by the people who ran the studies.
How does CagriSema (Cagrilintide) Work?
Dr Rob Swanda, science educator
A science educator explains how pairing the amylin analogue cagrilintide with semaglutide is meant to act on appetite and weight.
Plain-language mechanism explainer for a combination drug.
When options run out
Uses people turn to when standard treatment has failed.
Obesity with type 2 diabetes
- Who
- People with diabetes, who usually lose less weight on GLP-1 drugs alone.
- Evidence
- REDEFINE 2 phase 3: 15.7 percent weight loss at 68 weeks versus 3.1 percent on placebo. Below analyst hopes.
- Route
- FDA review of filed application
Source: BioSpace, 2025-03
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Questions people ask
When will CagriSema be approved?
It was filed with FDA in December 2025, and a decision is expected by the end of 2026. No decision had been announced by 12 October 2026, and no EU filing is confirmed.
How much weight loss does CagriSema give?
In REDEFINE 1 (3,417 people, 68 weeks), average loss was 22.7% among people who stayed on it and 20.4% counting everyone, against 3.0% on placebo.
Is CagriSema better than tirzepatide (Zepbound)?
Head to head, CagriSema reached 23% loss at 84 weeks but failed to show it was as good as the top dose of tirzepatide. In type 2 diabetes, a low dose beat low-dose tirzepatide on weight in REIMAGINE 5, 12.4% against 9.1%.
What are the side effects of CagriSema?
Stomach and bowel side effects affected about 80% of people in trials, against 40% on placebo, and about 6% stopped because of side effects. It also carries the known semaglutide risks.
What is in CagriSema?
Two peptides in one weekly injection: cagrilintide, a long-acting copy of the fullness hormone amylin, and semaglutide.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Novo Nordisk: CagriSema filed with FDA (18 Dec 2025)
- Novo Nordisk: REIMAGINE 5 and REDEFINE 9 results (21 Sep 2026)
- Drugs.com: CagriSema development timeline
Structure: PubChem